Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 7:49 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 1,130 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 0.9 Normal Saline Clear all

Conditions: Complex Regional Pain Syndromes
Interventions: Ketamine, Midazolam, Normal Saline; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2099
U.S. locations: 1
States / cities: Stanford, California

Conditions: Kidney Diseases
Interventions: YSPSL, placebo; Drug
Lead sponsor: Y's Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 15
States / cities: Los Angeles, California • San Francisco, California • Denver, Colorado + 11 more

Conditions: Osteoarthritis
Interventions: triamcinolone acetonide, saline; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 2
States / cities: La Jolla, California

Conditions: Respiratory Syncytial Virus
Interventions: mRNA-1345, Placebo; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 60 Years and older
Enrollment: 10,994 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 109
States / cities: Birmingham, Alabama • Guntersville, Alabama • Huntsville, Alabama + 93 more

Conditions: Human Immunodeficiency Virus
Interventions: Ad26.Mos4.HIV, MVA-Mosaic, Clade C gp140 + Mosaic gp140, Placebo; Biological · Drug
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Lumbar Spine Degeneration, Cervical Spine Degeneration
Interventions: saline 0.9%, (0.05% chlorhexidine gluconate (CHG) in sterile water); Drug
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: PSC
Interventions: Radiotracer Injection, Contrast Media, Magnetic Resonance, Imaging; Drug · Diagnostic Test
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 99 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Charlestown, Massachusetts

Conditions: Covid19
Interventions: VIR-7831 (sotrovimab), Placebo; Biological · Drug
Lead sponsor: Vir Biotechnology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,057 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 63
States / cities: Anniston, Alabama • Cullman, Alabama • Mesa, Arizona + 49 more

Conditions: Hepatorenal Syndrome
Interventions: Terlipressin; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 7
States / cities: San Francisco, California • Atlanta, Georgia • Boston, Massachusetts + 4 more

Conditions: Traumatic Brain Injury, Elevated Intracranial Pressure
Interventions: Mannitol, Hypertonic Saline; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years to 70 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Inguinal Herniorrhaphy
Interventions: CPL-01, Naropin 150 MG Per 20 ML Injection, Placebo; Drug
Lead sponsor: Cali Pharmaceuticals LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 5
States / cities: Sheffield, Alabama • Phoenix, Arizona • Anaheim, California + 2 more

Conditions: Blunt Trauma, Penetrating Wound, Hemorrhagic Shock
Interventions: 0.9% Sodium Chloride 250 mL bolus, 0.9% Sodium Chloride 2000 mL bolus; Drug
Lead sponsor: University of Washington; Other
Eligibility: 15 Years and older
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 5
States / cities: Birmingham, Alabama • Portland, Oregon • Pittsburgh, Pennsylvania + 2 more

Conditions: Pneumonia, Hypoxemia, Acute Respiratory Failure, COVID-19 Pneumonia
Interventions: Inhaled budesonide and formoterol, Inhaled placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 465 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 12
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 8 more

Conditions: Crohn Disease
Interventions: Placebo, Bacteriophage preparation; Biological
Lead sponsor: Intralytix, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2026
U.S. locations: 2
States / cities: Lutherville, Maryland • New York, New York

Conditions: Shock, Cardiogenic
Interventions: Dobutamine, Milrinone, Normal Saline; Drug
Lead sponsor: Ottawa Heart Institute Research Corporation; Other
Eligibility: 18 Years and older
Enrollment: 346 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Osteoarthritis, Articular Cartilage, Musculoskeletal Disorders
Interventions: Platelet-Rich Plasma (PRP) Injections, Centrifuge, Control saline injection; Drug · Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Severe Bronchopulmonary Dysplasia
Interventions: Albuterol Sulfate, Sterile Saline; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: Up to 1 Year
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Depression, Depression Severe, Depression Acute, Depression and Suicide, Suicidal Ideation
Interventions: Ketamine, Sodium Chloride 0.9%; Drug
Lead sponsor: MercyOne Des Moines Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Des Moines, Iowa

Conditions: Liver Failure
Interventions: Vasopressin, Normal saline placebo; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 80 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE, Prevention of Pneumococcal-induced Acute Otitis Media
Interventions: Inactivated whole-cell Streptococcus pneumoniae vaccine, Placebo; Biological · Drug
Lead sponsor: Serum Life Science Europe GmbH; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Patients Being Assessed With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson, Lexiscan
Interventions: Aminophylline, Placebo; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Plantar Fasciitis
Interventions: Injection of 1.0 cc of 0.9% Saline, Injection of 1.0 cc of 10 mg/ml micrograft dHACM suspension, Injection of 1.0 cc of 20 mg/ml micrograft dHACM suspension, Injection of 1.0 cc of 40 mg/ml micrograft dHACM suspension; Procedure
Lead sponsor: MiMedx Group, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Roanoke, Virginia

Conditions: Bilateral Primary Osteoarthritis of Knee
Interventions: Autologous Bone Marrow Aspirate Concentrate, Sterile saline; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 99 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Aging, Depression, Cognitive Symptom
Interventions: Cognitive Training, tDCS (active stimulation), tDCS (sham stimulation); Behavioral · Device
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 60 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Nashville, Tennessee

Search by objective public record fields.

Ketamine and Midazolam Infusions for CRPS: Feasibility Study

YSPSL for Prevention of Delayed Graft Function Part B

Using Ultrasound to Predict Response to Intraarticular Corticosteroids in Knee Osteoarthritis

Moderna Vaccine mRNA-1345 Observational Respiratory Syncytial Virus (RSV) Study

A Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Modified Vaccinia Ankara (MVA)-Mosaic OR Ad26.Mos4.HIV Plus a Combination of Mosaic and Clade C gp140 Protein in Human Immunodeficiency Virus (HIV) Type 1 Infected Adults on Suppressive Antiretroviral Treatment

Randomized Controlled Trial Comparing Irrisept Versus Normal Saline for Wound Irrigation After Posterior Spine Surgery

PET/MRI of Primary Sclerosing Cholangitis

VIR-7831 for the Early Treatment of COVID-19 in Outpatients

Terlipressin for HRS-AKI in Liver Transplant Candidates (INFUSE)

Hypertonic Saline vs. Mannitol for Elevated Intercranial Pressure

A Phase 2, Randomized, Double-Blind, Dose Escalation Study in Postoperative Pain Open Inguinal Herniorrhaphy

Field Trial of Hypotensive Versus Standard Resuscitation for Hemorrhagic Shock After Trauma

ARrest RESpiraTory Failure From PNEUMONIA

Safety and Efficacy of EcoActive on Intestinal Adherent Invasive E. Coli in Patients With Inactive Crohn's Disease

CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock

Platelet Rich Plasma Injections In Young And Old Human Subjects

Aerosolized Albuterol Use in Severe BPD

Effectiveness of Ketamine for Depression and Suicidal Ideation in the Emergency Department

Study to Evaluate if the Drug Vasopressin Protects the Kidneys for Patients Undergoing Liver Transplant

Safety Study of a Single Dose of Pneumococcal Whole-Cell Vaccine in Healthy Adults

Study With Aminophylline to Attenuate of the Side Effects of Regadenoson

Dehydrated Human Amnion/Chorion Membrane Micrografts(dHACM) Injectable in the Treatment of Recalcitrant Plantar Fasciitis

Use of Autologous Bone Marrow Aspirate Concentrate in Painful Knee Osteoarthritis

Cognitive Enhancement in Depression (The COG-D Study)